Living with Multiple System Atrophy (MSA) is a relentless challenge, but participating in cutting-edge research can offer hope and a sense of purpose. Recently, I had the opportunity to join the MyTrial program at Khurana Labs, located within Brigham and Women’s Hospital in Boston. This blog post details my experiences, particularly focusing on Day 3 of my journey.
Day 3 – 1 PM: CLIMB Enrollment
https://www.brighamandwomens.org/neurology/movement-disorders/clinical-studies-and-trials
My agenda for Day 3 included enrollment in the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) Study. Although primarily designed for multiple sclerosis (MS), the CLIMB Study also enrolls patients with other neurodegenerative diseases, including MSA. This enrollment is pivotal in helping researchers understand the complex interplay of factors that influence these diseases.
The CLIMB Study involves a blood draw, which is used to identify neuroinflammatory biomarkers. These biomarkers provide a profile of the different cell types in the immune system. Understanding the immune system’s role is crucial, as it can help determine how inflammation might contribute to the progression of MSA. This kind of data is invaluable for developing new therapeutic strategies and potentially slowing the disease’s progression.
In addition to blood samples, the study also includes stool sampling. This may sound unusual, but it is a critical component. The stool samples allow researchers to examine the gut microbiome, which can be impacted by neurodegenerative diseases and might also play a role in their onset. By studying the gut microbiome, scientists hope to uncover new insights into how gut health relates to neurological health.
Collaborating with Harvard Biomarker Study
The MyTrial program works closely with two significant studies to collect biomarkers and biometrics. The first of these is the Harvard Biomarker Study (HBS), one of the largest biobanks for Parkinson’s disease and other neurodegenerative diseases globally. HBS matches these biomarkers to clinical and genetic data, aiming to identify susceptibilities such as genetic variants and environmental exposures that lead to these diseases. Additionally, it helps track disease progression.
The Importance of CLIMB and HBS
Both the CLIMB and HBS studies are integral to advancing our understanding of neurodegenerative diseases. For patients like me, participating in these studies offers a dual benefit. On one hand, we contribute to research that may one day lead to better treatments or even a cure. On the other hand, we gain access to cutting-edge diagnostics and monitoring, potentially leading to more personalized and effective management of our conditions.
Reflections on the Journey
As I reflect on my participation in the MyTrial program, I am filled with a sense of hope and purpose. The collaboration between Khurana Labs, HBS, and the CLIMB Study exemplifies the power of scientific research and its potential to transform lives. While living with MSA is challenging, being part of this research gives me a proactive role in the fight against neurodegenerative diseases.
Each day at Khurana Labs has been a step forward, not just for me, but for the countless individuals affected by similar conditions. Through programs like MyTrial, we are not just subjects of study but active participants in the journey toward better understanding and eventual breakthroughs.
Final Thoughts
Enrolling in the CLIMB Study was a significant milestone in my journey with MSA. It represents more than just participation in a research program; it is a beacon of hope for the future. I encourage anyone eligible for such programs to consider joining. Your involvement could make a profound difference, not only in your own life but in the lives of countless others who are battling neurodegenerative diseases. Together, we can climb toward a brighter, healthier future.
~Coach~
Living Beyond the Diagnosis 
Leave a comment